ASCPT SIGN IN
Username:
Password:
SEARCH

Translational Bytes
To read the full post, please click on the title.

Get Smart(er)
Genome-wide analysis technologies enabled the exploration of a whole new universe of DNA sequence variations that contribute to the development and progression of common, complex diseases. While genome-wide approaches have been highly productive, a significant challenge remains after more than a decade of hypothesis-free genomics research...[read more]
Eating Olives Increases Plasma Catechols, so Does My Martini Have Health Benefits?
Eating olives has been implicated with a plethora of health benefits including cardiovascular benefits, cancer prevention, antioxidant effects, and many others. In addition to being found in martinis, olives are an important component of the Mediterranean diet. In fact, the catechol dihydroxyphenylethanol (DOPET), which is abundant in olives, has been identified as a nutraceutical and proposed to contribute to these Mediterranean diet health benefits...[read more]
Patient Enrichment Strategies for Accelerated Drug Approval
Oncology drug development has pioneered the use of biomarker-driven patient selection for clinical trials, and other therapeutic areas would benefit from similar approaches. Novel therapeutics that target a specific mutation(s) in a gene or set of genes in a critical signaling pathway, or that target cancer cells with a specific pattern of gene expression, are expected to benefit a well-defined subset of patients. It is then a logical step to...[read more]
In 2011, the International Rare Diseases Research Consortium (IRDiRC) was launched across stakeholders to create a common public and private sector vision and approach to rare diseases. In 2017, the IRDiRC has exhibited substantial progress towards ambitious goals of developing 200 new therapies and the means to diagnose most rare genetic diseases by the year 2020. Progress and the future vision were recently highlighted in two Clinical and Translational Science articles...[read more]
Drug-Drug Interactions Lost in Translation
Several analyses have previously demonstrated the delay of translating new information of clinically significant drug-drug interactions (DDIs) to drug labels, and the lack of consistency of drug-drug interaction labeling between the interacting drugs. The brief report...[read more]

 

 

RSS
12345678
528 N Washington St, Alexandria, VA 22314 |  Ph: 703.836.6981 |  info@ascpt.org